People living with HIV are more than 14 times more likely to fall ill with TB disease than people without HIV.

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

A groundbreaking annual injection designed to protect against HIV has successfully passed its first safety trial, bringing new hope for long-term prevention.The drug, Lenacapavir, prevents the virus ...

Prof. Francisca Mutapi, a global health expert suggests 4 ways to end the dependence HEALTH | FRANCISCA MUTAPI | There’s been a global trend in the reduction of aid to Africa since 2018. Donors are ...

Malawians must brace for more tough times following the United Sates of America’s (USA) decision to terminate contracts worth ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A new study in Australia found that treating male partners can reduce BV reinfections, suggesting that BV may be sexually ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...